SPOT ON
From valsartan to Lunapharm … what are the consequences?

THERAPY FROM A CRITICAL VIEWPOINT
New indication – rivaroxaban (XARELTO) for stable coronary heart disease and peripheral arterial disease

a-t READERS QUESTIONS AND COMMENTS
Aluminium in vaccines

IN BRIEF
Antidepressant agomelatine (VALDOXAN) – risk mitigation measures are not followed
ALZHEIMERs drugs no longer reimbursed in France free article
Supply shortage – expiry dates of epinephrine auto-injectors extended
Diabetes – omega-3 fatty acids for cardiovascular prevention?
Vacuum wound treatment – data under lock and key

SIDE EFFECTS
Diabetes mellitus: FOURNIER gangrene with SGLT-2 inhibitors
Daclizumab: encephalitis even months after discontinuation
Restrictions of use of IBEROGAST – 10 years too late

e a-t ON THE INTERNET
“Flu” vaccines 2018/19